CELL INTELLIGENCE · 肿瘤细胞治疗研究

胶质母细胞瘤的代谢与翻译后脆弱性：二硫死亡、糖基化及对 CAR-T 治疗的启示

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.

经巨噬细胞靶向 EGFR(VIII) 突变胶质母细胞瘤细胞的新型嵌合抗原受体（CAR）策略

A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFR(VIII)-mutated glioblastoma cells via macrophages.

本工作所描述的模型适合用于向 iPSC 来源巨噬细胞的转化，以在表达突变变体 EGFR VIII 的实体瘤中产生未来可临床应用的细胞治疗方法。

胶质母细胞瘤：流行病学、分类、发病机制、诊断与治疗的当代概述——综述文章

Glioblastoma-A Contemporary Overview of Epidemiology, Classification, Pathogenesis, Diagnosis, and Treatment: A Review Article.

胶质母细胞瘤中通过 HLA I 类分型和 AlphaFold2-Multimer 进行整合性新抗原发现

Integrative Neoepitope Discovery in Glioblastoma via HLA Class I Profiling and AlphaFold2-Multimer.

胶质母细胞瘤的嵌合抗原受体 (CAR)-T 细胞治疗：早期临床试验的启示——一项系统综述

Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review.

几种 CAR-T 策略目前已在胶质母细胞瘤中进行了初步试验。似乎存在疗效信号，128 例报告患者中有 56 例显示出至少某种程度的缓解。CAR-T 细胞的中枢递送似乎是安全的，剂量高达 2.5 10 7 细胞耐受良好。后续的 CAR-T 试验应标准化结局报告，以便更好地跨试验比较。

体外评估基因未修饰的配体武装异体 NK 细胞治疗 EGFR 阳性胶质母细胞瘤

In Vitro Evaluation of Genetically Unmodified Ligand-Armed Allogeneic Natural Killer Cells to Treat EGFR-Positive Glioblastoma.

H3K27M 突变型弥漫性内生性脑桥胶质瘤管理的最新进展：一项叙述性综述

Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review.

分子生物标志物在复发性胶质母细胞瘤试验中的作用：对基因组驱动肿瘤学当前试验格局的评估

The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology.

儿童大脑半球高级别胶质瘤与 H3.3-G34 突变：生物学特征与新治疗策略的文献综述

Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies.

革新胶质母细胞瘤治疗：现代治疗方法的全面概述

Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.